“…The 31 effect sizes across nine studies (Montemayor, 2014; Phipps, 2017; Robinson, Simpson, & Hott, 2017; Schottelkorb & Ray, 2009; Schottelkorb, Swan, Jahn, Haas, & Hacker, 2015; Swan & Ray, 2014; Swank, Shin, Cabrita, Cheung, & Rivers, 2015; Wixson, 2014) included in the analysis of CCPT for reducing externalizing symptoms yielded an omnibus Tau-U effect size of .43 (95% CI = .28, .56), p < .01, indicative of a moderate effect size and suggesting that the null hypothesis related to therapeutic superiority of CCPT when compared to no treatment can be rejected. Convergent evidence was detected through inspection of an omnibus PEM estimate of 67%, which is within the debatable range of nonoverlap associated desired treatment response.…”